NuCana plc
Index- P/E- EPS (ttm)-0.97 Insider Own0.35% Shs Outstand52.18M Perf Week-0.32%
Market Cap31.05M Forward P/E- EPS next Y-53.83 Insider Trans0.00% Shs Float51.66M Perf Month-29.82%
Income-50.50M PEG- EPS next Q-16.35 Inst Own29.80% Short Float0.80% Perf Quarter-78.52%
Sales- P/S- EPS this Y3.80% Inst Trans-28.23% Short Ratio0.83 Perf Half Y-77.63%
Book/sh1.57 P/B0.38 EPS next Y-11.20% ROA-45.00% Target Price9.20 Perf Year-80.80%
Cash/sh1.44 P/C0.41 EPS next 5Y- ROE-50.90% 52W Range0.52 - 3.35 Perf YTD-75.00%
Dividend- P/FCF- EPS past 5Y-31.80% ROI- 52W High-81.49% Beta0.62
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low19.90% ATR0.06
Employees31 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)32.96 Volatility7.86% 10.07%
OptionableNo Debt/Eq0.01 EPS Q/Q-9.30% Profit Margin- Rel Volume0.27 Prev Close0.60
ShortableYes LT Debt/Eq0.00 EarningsApr 27 AMC Payout- Avg Volume496.84K Price0.62
Recom1.40 SMA20-3.37% SMA50-25.72% SMA200-69.93% Volume132,477 Change4.18%
Mar-03-22Downgrade Cowen Outperform → Market Perform
Oct-22-20Initiated Truist Buy $22
Jul-24-20Initiated Oppenheimer Outperform
Aug-19-19Initiated H.C. Wainwright Buy $20
Oct-19-18Initiated Piper Jaffray Overweight
Oct-23-17Initiated William Blair Outperform
Oct-23-17Initiated Jefferies Buy $25
Oct-23-17Initiated Citigroup Buy $23
May-06-22 07:59AM  
Apr-27-22 04:01PM  
Mar-15-22 11:09AM  
Mar-08-22 04:35PM  
Mar-04-22 10:00AM  
Mar-03-22 06:13AM  
Mar-02-22 04:01PM  
Feb-28-22 04:01PM  
Feb-22-22 04:01PM  
Feb-01-22 10:53AM  
Jan-24-22 09:40AM  
Dec-28-21 09:38AM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-08-21 09:38AM  
Nov-18-21 04:01PM  
Nov-10-21 08:00AM  
Nov-01-21 04:01PM  
Sep-30-21 10:18AM  
Sep-29-21 12:20PM  
Sep-16-21 08:00AM  
Sep-15-21 08:00AM  
Sep-01-21 08:00AM  
Aug-19-21 04:01PM  
Aug-10-21 08:00AM  
Aug-02-21 07:11AM  
May-25-21 08:00AM  
May-19-21 04:01PM  
May-03-21 07:42AM  
Apr-28-21 08:00AM  
Apr-10-21 08:30AM  
Mar-04-21 04:01PM  
Feb-25-21 08:00AM  
Feb-01-21 05:19AM  
Jan-15-21 08:01AM  
Jan-12-21 11:39AM  
Jan-11-21 08:46AM  
Dec-21-20 04:01PM  
Dec-07-20 11:03PM  
Dec-01-20 08:08AM  
Nov-30-20 04:01PM  
Nov-19-20 04:01PM  
Nov-17-20 04:01PM  
Nov-12-20 04:01PM  
Nov-10-20 08:59AM  
Nov-03-20 08:16AM  
Oct-13-20 04:01PM  
Oct-02-20 08:00PM  
Sep-24-20 08:31AM  
Sep-21-20 04:02PM  
Sep-17-20 07:00AM  
Sep-16-20 04:01PM  
Aug-19-20 04:01PM  
Aug-18-20 09:46AM  
Aug-05-20 09:10AM  
Jul-31-20 12:34PM  
Jul-24-20 03:25PM  
Jul-02-20 12:25PM  
Jun-29-20 12:49PM  
Jun-24-20 11:53AM  
Jun-18-20 10:23AM  
Jun-16-20 10:47AM  
Jun-10-20 01:04PM  
Jun-02-20 08:59AM  
Jun-01-20 12:20PM  
May-28-20 10:54AM  
May-27-20 09:34AM  
May-24-20 07:00AM  
May-19-20 04:01PM  
May-18-20 07:00AM  
May-15-20 07:00AM  
May-05-20 04:01PM  
Apr-02-20 04:01PM  
Mar-18-20 08:25AM  
Mar-11-20 08:03AM  
Mar-10-20 04:02PM  
Mar-04-20 07:00AM  
Feb-29-20 07:00AM  
Feb-25-20 09:46AM  
Jan-27-20 07:00AM  
Jan-03-20 10:54AM  
Dec-20-19 05:44PM  
Dec-11-19 07:04AM  
Nov-27-19 03:32AM  
Nov-26-19 07:00AM  
Nov-22-19 10:48AM  
Nov-20-19 09:50AM  
Nov-14-19 07:00AM  
Nov-13-19 04:01PM  
Oct-29-19 07:00AM  
Oct-25-19 07:00AM  
Oct-17-19 11:24AM  
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.